General
Preferred name
Torasemide
Synonyms
TORSEMIDE ()
AC-4464 ()
JDL-464 ()
TORASEMIDE56211-40-6 ()
AC-4464, JDL-464 ()
Soaanz ()
Upcard ()
BM02.015 ()
AC4464 ()
BM-02.015 ()
Demadex ()
Torasemide anhydrous ()
Isemid ()
Luprac ()
Torem 5 ()
Torem 10 ()
BM-02015 ()
Torem 2.5 ()
Torasemida ()
Torasemide ()
Torasemide-d7 ()
P&D ID
PD000562
CAS
56211-40-6
1189375-06-1
Tags
available
drug
Approved by
FDA
First approval
1993
Drug indication
Cardiovascular disease
Congestive heart failure
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Torsemide is a loop diuretic.
(GtoPdb)
HALF-LIFE
The average half-life of torasemide is 3.5 hours.[A174472]
ROE
Torasemide is mainly hepatically processed and excreted in the feces from which about 70-80% of the administered dose is excreted by this pathway. On the other hand, about 20-30% of the administered dose is found in the urine.[L5257]
MOA
As mentioned above, torasemide is part of the loop diuretics and thus, it acts by reducing the oxygen demand in the medullary thick ascending loop of Henle by inhibiting the Na+/K+/Cl- pump on the luminal cell membrane surface.[A174466] This action is obtained by the binding of torasemide to a chloride ion-binding site of the transport molecule.[L5257] Torasemide is known to have an effect in the renin-angiotensin-aldosterone system by inhibiting the downstream cascade after the activation of angiotensin II. This inhibition will produce a secondary effect marked by the reduction of the expression of aldosterone synthase, TGF-B1 and thromboxane A2 and a reduction on the aldosterone receptor binding.[A174466, A174472]
INDICATION
Torasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure.[FDA label] Edema is considered when swelling is observed due to the trap of fluid in the body tissue. It is mainly located in feet, ankles and legs but it can also be extended to other parts such as face, hands and abdomen or even the whole body.[L5251] As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.[FDA label] Hypertension is defined by the presence of high blood pressure. This is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteries.[L5254]
TOXICITY
The oral LD50 of torasemide in the rat is 5 g/kg. When overdose occurs, there is a marked diuresis with the danger of loss of fluid and electrolytes which has been seen to lead to somnolence, confusion, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, hemoconcentration dehydration and circulatory collapse. This effects can include some gastrointestinal disturbances.[L5260] There is no increase in tumor incidence with torasemide and it is proven to not be mutagenic, not fetotoxic or teratogenic.[FDA label]
MOA
As mentioned above, torasemide is part of the loop diuretics and thus, it acts by reducing the oxygen demand in the medullary thick ascending loop of Henle by inhibiting the Na+/K+/Cl- pump on the luminal cell membrane surface.[A174466] This action is obtained by the binding of torasemide to a chloride ion-binding site of the transport molecule.[L5257]; ; Torasemide is known to have an effect in the renin-angiotensin-aldosterone system by inhibiting the downstream cascade after the activation of angiotensin II. This inhibition will produce a secondary effect marked by the reduction of the expression of aldosterone synthase, TGF-B1 and thromboxane A2 and a reduction on the aldosterone receptor binding.[A174466, A174472]
TOXICITY
The oral LD50 of torasemide in the rat is 5 g/kg. When overdose occurs, there is a marked diuresis with the danger of loss of fluid and electrolytes which has been seen to lead to somnolence, confusion, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, hemoconcentration dehydration and circulatory collapse. This effects can include some gastrointestinal disturbances.[L5260]; ; There is no increase in tumor incidence with torasemide and it is proven to not be mutagenic, not fetotoxic or teratogenic.[FDA label]
METABOLISM
Torasemide is extensively metabolized in the liver and only 20% of the dose remains unchanged and it is recovered in the urine.[A174475] Metabolized via the hepatic CYP2C8 and CYP2C9 mainly by reactions of hydroxylation, oxidation and reduction to 5 metabolites.[A174514] The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.[A174508]
PHARMACODYNAMICS
It is widely known that administration of torasemide can attenuate renal injury and reduce the severity of acute renal failure. This effect is obtained by increasing urine output and hence, facilitating fluid, acid-base and potassium control.[A174466] This effect is obtained by the increase in the excretion of urinary sodium and chloride.[A174472] Several reports have indicated that torasemide presents a long-lasting diuresis and less potassium excretion which can be explained by the effect that torasemide has on the renin-angiotensin-aldosterone system. This effect is very similar to the effect observed with the administration of combination therapy with [furosemide] and [spironolactone] and it is characterized by a decrease in plasma brain natriuretic peptide and improved measurements of left ventricular function.[A174472] Above the aforementioned effect, torasemide presents a dual effect .in which the inhibition of aldosterone which donates torasemide with a potassium-sparing action.[A174466] Torasemide has been shown to reduce extracellular fluid volume and blood pressure in hypertensive patients suffering from chronic kidney disease. As well, some reports have indicated that torasemide can reduce myocardial fibrosis by reducing the collagen accumulation. This effect is suggested to be related to the decrease in aldosterone which in order has been shown to reduce the production of the enzyme procollagen type I carboxy-terminal proteinase which is known to be overexpressed in heart failure patients.[A174463]
ABSORPTION
Torasemide is the diuretic with the highest oral bioavailability even in advanced stages of chronic kidney disease.[A174463] This bioavailability tends to be higher than 80% regardless of the patient condition. The maximal serum concentration is reported to be of 1 hour and the absorption parameters are not affected by its use concomitantly with food.[A174472]
PHARMACODYNAMICS
It is widely known that administration of torasemide can attenuate renal injury and reduce the severity of acute renal failure. This effect is obtained by increasing urine output and hence, facilitating fluid, acid-base and potassium control.[A174466] This effect is obtained by the increase in the excretion of urinary sodium and chloride.[A174472]; ; Several reports have indicated that torasemide presents a long-lasting diuresis and less potassium excretion which can be explained by the effect that torasemide has on the renin-angiotensin-aldosterone system. This effect is very similar to the effect observed with the administration of combination therapy with [furosemide] and [spironolactone] and it is characterized by a decrease in plasma brain natriuretic peptide and improved measurements of left ventricular function.[A174472] ; ; Above the aforementioned effect, torasemide presents a dual effect .in which the inhibition of aldosterone which donates torasemide with a potassium-sparing action.[A174466]; ; Torasemide has been shown to reduce extracellular fluid volume and blood pressure in hypertensive patients suffering from chronic kidney disease. As well, some reports have indicated that torasemide can reduce myocardial fibrosis by reducing the collagen accumulation. This effect is suggested to be related to the decrease in aldosterone which in order has been shown to reduce the production of the enzyme procollagen type I carboxy-terminal proteinase which is known to be overexpressed in heart failure patients.[A174463]
INDICATION
Torasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure.[FDA label]; ; Edema is considered when swelling is observed due to the trap of fluid in the body tissue. It is mainly located in feet, ankles and legs but it can also be extended to other parts such as face, hands and abdomen or even the whole body.[L5251]; ; As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.[FDA label]; ; Hypertension is defined by the presence of high blood pressure. This is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteries.[L5254]
DESCRIPTION
Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis[1][1][3].
PRICE
29
DESCRIPTION
Torasemide is a high-ceiling loop diuretic. It is used as an antihypertensive agent. It acts by reducing the oxygen demand in the medullary thick ascending loop of Henle by inhibiting the Na+/K+/Cl- pump on the luminal cell membrane surface.
(Enamine Bioactive Compounds)
DESCRIPTION
Torsemide (AC-4464) is an anilinopyridine sulfonylurea belonging to the class of loop diuretics. Torsemide has a prolonged duration of action compared to other loop diuretics, is extensively protein bound in plasma and has a relatively long half-life.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
25
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
84
Molecular Weight
348.13
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
2.53
TPSA
100.19
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Na-K-Cl cotransporter
SLC12A1
Chloride channel
NKCC
MOA
Na-K-Cl cotransporter inhibitor
Drugs Acting on Potassium Channels
electrolyte reabsorption inhibitor, thromboxane receptor antagonist
Member status
member
Indication
edema, congestive heart failure, hypertension
Therapeutic Class
Diuretics
Pathway
Membrane Transporter/Ion Channel
Source data

